LYFE, GL Ventures & Lilly Asia Advance RNA Drug Development
27 Oct 2025
US$ 20.00
LYFE Capital, along with GL Ventures and Lilly Asia Ventures (LAV), has co-led the Rmb300 m (US$42 m) plus Series B ......
Related Publications
US-based Gates Foundation has participated in the A$34 m (US$22.4 m) series B financing round of Ena Respiratory Pty ......
Singapore-based Pentagreen Capital, a sustainable infrastructure debt financing company that counts HSBC Holdings ......
Connect With Us
We love to share Asia PE insights and news from time to time. Drop us your email address if you like to hear from us.
Rest assured that your email address will not be shared, as we hate spams as much as you do.